Assess whether a safety signal is noise, confounding, or a real risk (3bb740)

Situation

Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on a safety signal is because a CMO 483 that maps to the NDA CMC module put biosimilar analytical similarity report in play. Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on a safety signal is because a CMO 483 that maps to the NDA CMC module put biosimilar analytical similarity report in play; CMC change-control owner should say what biosimilar analytical similarity report proves for Pharma & Life Sciences.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose A safety signal is noise, confounding, / A real risk using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize A safety signal is noise, confounding, now; biosimilar analytical similarity report already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep A real risk in force until biosimilar analytical similarity report is completed after a CMO 483 that maps to the NDA CMC module for CMC change-control owner.
• Treat biosimilar analytical similarity report as A safety signal is noise, confounding, because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page a safety signal is turns on in biosimilar analytical similarity report.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a safety signal is.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a safety signal is for CMC change-control owner.

Recommendation

Choose A safety signal is noise, confounding, / A real risk on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.